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Abstract
Background and objective : Despite the growing evidence on the benefits of self-monitoring in diabetes,
the use of these meters has been low in developing countries, particularly India. Cost seems to be the
major constraint. The aim of the present study is to evaluate the accuracy of One Touch HORIZON an
affordable glucose meter with laboratory assessment of blood glucose.
Methods : 100 subjects with diabetes over the age of 18 years were recruited from the MV Diabetes
Specialities Centre, Chennai. All the study subjects had their fasting blood tested for glucose in One
Touch HORIZON by finger prick. Fasting blood glucose was also assessed in YSI 2300 STATPLUS
(Yellow Springs Instruments, Ohio, USA) glucose analyzer. The Parke’s Error Grid model was used to
assess the accuracy of the meter against YSI plasma glucose values.
Results : Of the total 100 study subjects, 97 were Type 2 diabetic subjects and three were Type 1
diabetic subjects. 62% of the study subjects were males. 89% did not perform SMBG and only 2% of the
diabetic subjects performed SMBG daily. The Parke’s Error Grid analysis revealed 97% of results to be
in Zone A when patient performed the test, 99 - 100% in Zone A when clinical staff performed the test
indicating excellent accuracy and precision.
Conclusion : One Touch HORIZON meter is an affordable meter with good accuracy and precision,
specifically designed to cater to the needs of diabetic patients in developing countries. ©
self-monitoring in diabetes, the use of these meters has been
exceedingly low in developing countries in contrast to
developed countries.  In USA, as early as 1989, 26% of type
2 diabetic subjects and 40% of type 1 diabetic subjects
performed SMBG at least once daily.6 During the last decade,
the usage of SMBG has tremendously increased as seen in
the recent Fremantle Diabetes Study, where 73.8% of diabetic
subjects performed SMBG.7 In contrast, in the CURES study,
the methodology of which has been reported elsewhere,8 we
found that less than 0.2 % of the diabetic subjects possess a
glucometer and virtually none tested blood sugars daily
[unpublished data]. One of the major barriers to perform
SMBG in developing countries is the cost of the meter. Other
factors include unawareness of the benefits of monitoring or
the complications of the disease and inability to learn due to
psychological or social barriers. However cost was the major
deterrent for over 60% of the population.  This emphasizes
the need for an affordable glucose meter. The appendix traces
the development of the One Touch HORIZON, a new
affordable glucose meter specifically developed to cater to
the needs of developing countries like India. This study
evaluates the accuracy of One Touch HORIZON in
comparison to laboratory assessment of blood glucose.
Madras Diabetes Research Foundation, Gopalapuram, Chennai,
India.
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Two landmark studies, the Diabetes Control andComplications Trial (DCCT) and the UK Prospective
Diabetes Study (UKPDS) have clearly documented that
maintenance of near normal blood glucose values by intensive
therapy reduces the incidence of diabetes complications,
particularly microvascular complications.1,2 Tight diabetes
control however mandates regular monitoring of blood
glucose levels to achieve the target. In the intensive therapy
group of the DCCT, self-monitoring of blood glucose [SMBG]
was performed at least four times per day.1 An observational
study on 807 type 1 diabetic patients showed that SMBG
was associated with improved glycemic control.3 The Auto-
Surveillance Intervention Active (ASIA) study showed similar
observations in type 2 diabetic subjects.4 Importance of self-
monitoring of blood glucose has led to the invention of several
blood glucose meters that have been extensively evaluated
and used all over the world as they are accurate and precise.5
However, despite the growing evidence on the benefits of
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MATERIAL AND METHODS
Study site: The study was conducted on 300 study
subjects recruited at three centres - two in the UK and one in
India (the Madras Diabetes Research Foundation and the
M.V.Diabetes Specialities Centre at Chennai). However this
paper only deals with data on the 100 subjects recruited at
the Chennai centre.
Study subjects: Type 1 or Type 2 diabetic subjects who
satisfied the inclusion-exclusion criteria were included for
the study i.e. study patients should be at least 18 years of
age and must be fasting at the time of blood draw. Pregnant
women were excluded from the study.
One Touch HORIZON glucose monitoring system: This
meter was developed keeping in mind the need to maximize
the ease of use for patients while at the same time limiting the
cost of the device.  A picture of the meter is shown in Fig. 1.
Standard laboratory test for glucose assessment: In order
to maintain uniformity among all study centres, YSI 2300
STATPLUS (Yellow Springs Instruments, Ohio, USA) glucose
analyzer was used for laboratory assessment of plasma
glucose values. For this analysis, blood from the finger prick
was collected using a capillary tube.
Study design: The study was conducted in three steps, in
step 1 all study patients tested their blood glucose level in
the One Touch HORIZON glucometer by themselves. In step
2, from the same finger prick, the clinical staff of the centre
loaded the sample on the One Touch HORIZON test strip. In
step 3, on the same patients, a clinic staff performed another
finger prick and then performed the blood glucose assessment
using both One Touch HORIZON and YSI machines.
The total testing time from performing finger prick to
measuring blood glucose values using both One Touch
HORIZON and YSI did not exceed 10 minutes.
Sample size calculation: In line with NCCLS (Section Ep9)
and ISO/FDIS 15197 guidance documents, a minimum sample
size of 50 patients will provide sufficient quantitative data to
compare the clinical accuracy of the test systems and
reference instruments. We set a target of 100 patients who
had to be recruited within a week’s time.
Statistical analysis: The results obtained from the One
Touch HORIZON glucometer were plotted on a Parke’s Error
grid method for assessment. This error grid is created to
identify if the discrepancies in the assessment of blood
glucose by new devices affect the clinical action taken for
the disease. Parke’s  grid method has eight zones, Zone A
represents no effect on clinical action, Zone B represents
altered clinical action but little or no effect on clinical outcome,
Zone C represents altered clinical action which was likely to
affect clinical outcome, Zone D represents altered clinical
action which could have a significant medical risk and Zone
E represents altered clinical action which could have
dangerous consequences.9
RESULTS
Table 1 presents the demographic details of the study
subjects. 62% of the study population was males. There were
97 Type 2 and three Type 1 diabetic subjects. Oral
hypoglycemic agents were the most common therapy followed
by diet and exercise and insulin. 89% of patients did not
perform SMBG at all and only 2% of diabetic subjects
performed SMBG daily.
Fig. 2 shows the age distribution and duration of diabetes
distribution in the study population. The mean age was 54 ±
13 years and the mean duration of diabetes was 11.7 ± 6.4
years.
The Parke’s Error Grid model was used to assess the
accuracy of the meter against YSI plasma glucose values and
the results are shown in Fig. 3. When tests were entirely
performed by the patients 97% of the results were in ZONE A
indicating excellent accuracy and good clinical utility (Fig.
3A). When the clinical staff performed the tests, 99% - 100%
of the results fell ZONE A reflecting excellent accuracy and
precision [Figs. 3B and 3C].
DISCUSSION
The One Touch HORIZON glucometer evaluated in this
study is a new product specifically designed to meet the
needs of developing countries. The meter was evaluated
against laboratory blood glucose assessment. The study
findings indicate that One Touch HORIZON is a reliable device
with good accuracy and precision as seen from the Parke’s
Error grid model. Further, as the patients, majority of whom
did not perform SMBG earlier were able to test their blood
glucose themselves, the study also suggests that the meter
Table 1 : Demographic details of the study subjects
Demographic Percentage (%)
n 100
Males 62%
Type 2: Type 1 diabetes 97:3
Therapy *
Diet and exercise alone 47%
Oral hypoglycemic agents 78%
Insulin (%) 34%
Use of SMBG
< 1 time / day 9 %
1 - 2 times / day 2 %
3 - 4 times / day —
> 5 times / day —
Does not test at all  (%) 89 %
* Numbers do not add up as some patients have more than 1 type
of treatment
Fig. 1 :  Picture of One Touch HORIZON meter
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is user friendly and has very minimal error rate.
As early as 1994, the American Diabetes Association
emphasized the role of SMBG and suggested it to be an
important component of diabetes treatment.6 However,
awareness of diabetes per se seems to be very poor in
developing countries like India and thus the awareness about
benefits of SMBG is probably even less. This is very
disturbing as India leads the world in the prevalence of
diabetes with over 31 million diabetic subjects and these
numbers are expected to increase to 79.4 by the year 2030.10
This places a large proportion of diabetic subjects at risk of
developing micro and macro vascular complications.  By
regularly performing SMBG, it is likely that diabetes
complications can be reduced considerably as better glucose
control can be achieved.
In this study, only 11% of the participants at a primary
diabetes centre in India performed SMBG as against 90% in
the UK centres. This is similar to that reported in Italy in 2001
by Franciosi et al.11 If this is the scenario among diabetic
patients attending a tertiary care centre in India where diabetic
patients are regularly educated about the importance of
SMBG, the situation in the general population would be much
worse. As already stated less than 0.2% of the diabetic
population in Chennai perform SMBG and even these
individuals do not perform SMBG on daily basis.
Since cost of the meter appears to be the major limiting
factor, the One Touch HORIZON meter has been designed
for developing countries like India by emphasizing efficiency
in design and by limiting features to those that are most
essential to the majority of patients. This allows the meter to
be made available at a lower cost than other meters and, as
the machine is accurate and precise, it is indeed a boon for
diabetic patients in India and other developing countries.
The cost of  strips may also be a barrier to glucose testing.
However the 10’s pack that has been introduced for the first
time in India means that the initial outlay can be much smaller.
Also it is likely that there will be less wastage of strips as it is
unlikely that the strips would cross the expiry date. The One
Touch HORIZON meter is truly a tribute to a group of Asian
diabetologists who got together and persuaded a
multinational company to produce a meter to specifically cater
to the needs of diabetic patients in developing countries.
Appendix  : Background of the One Touch HORIZON
blood glucose meter
The One Touch HORIZON meter is a unique contribution
of key opinion leaders (diabetologists) of Asia who laid down
the criteria for development of an affordable, user friendly
and accurate meter for developing countries. Indian
diabetologists who were part of the ‘think - tank’ for One
Touch HORIZON were Dr. Shashank Joshi (Mumbai), Dr.
Shishir Kumar (Mumbai), Dr. SK Wangnoo (New Delhi) and
Dr. V Mohan (Chennai). Based on the specifications and
conditions laid down by the key opinion leaders from Asia,
the machine was developed by M/s. Lifescan Johnson and
Johnson. The clinical trials were carried out at three centres
(1) Madras Diabetes Research Foundation and MV Diabetes
Specialities Centre,  (Chennai, India) (2) New Royal Infirmary
(Edinburgh, UK) (3) Birmingham Heartlands Hospital
(Birmingham, UK). In this paper only the data from India is
presented. However the data from the other centres in UK
were virtually identical to that obtained at the Indian centre.
Johnson and Johnson Medical has commercial interest in
the article with their product OneTouch HorizonTM
Fig. 2 : Age distribution (Fig 2A) and duration of diabetes (Fig 2B)
distribution of the study population
Fig. 3: Clinical accuracy of One Touch HORIZON - Parke’s Error Grid
A: Patients performed finger prick and loaded the blood samples on
     One Touch HORIZON test strip  - 97% Zone A
B: Patients performed finger prick and clinical staff loaded the blood
     samples on One Touch HORIZON test strip -  99% Zone A
C: Clinical staff performed the finger prick and loaded the blood
samples on One Touch HORIZON test strip -  100% Zone A
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